PTGX vs KYMR vs IMVT vs BMY

For growth investors, Bristol-Myers Squibb Company (BMY) is the stronger pick with -0.

2% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Protagonist Therapeutics, Inc. (PTGX) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8.

9x.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +238. 8%, compared to +5. 2% for Bristol-Myers Squibb Company (BMY). Over 10 years, the gap is even starker: PTGX returned +749. 2% versus BMY's +6. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 23β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 491% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bristol-Myers Squibb Company (BMY) is pulling ahead at -0.

2% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bristol-Myers Squibb Company (BMY) is the more profitable company, earning 14.

6% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMY leads at 26. 3% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8.

9x forward P/E versus 30. 6x for Protagonist Therapeutics, Inc. — 21. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IMVT: 67. 2% to $45. 50.

In this comparison, BMY (4.

4% yield) pays a dividend. PTGX, KYMR, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 23), +749. 2% 10Y return). Both have compounded well over 10 years (PTGX: +749. 2%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PTGX is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; BMY is a mid-cap deep-value stock. BMY pays a dividend while PTGX, KYMR, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.